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Purpose: During Stereotactic Body Radiotherapy (SBRT) for the treatment of prostate cancer, an inflatable
endorectal balloon (ERB) may be used to reduce motion of the target and reduce the dose to the posterior
rectal wall. This work assessed the dosimetric impact of manual interventions on endorectal balloon position
in patients receiving prostate SBRT, and investigated the impact of ERB interventions on prostate shape.
Methods: The data of seven consecutive patients receiving SBRT for the treatment of clinical stage
T1cN0M0 prostate cancer enrolled in a multi-institutional, IRB-approved trial were analyzed. The SBRT
dose was 50 Gy in 5 fractions to a planning target volume (PTV) that included the prostate (implanted with
three fiducial markers) with a 3 mm margin. All plans were based on simulation images that included an
ERB inflated with 60 cm3 of air. Daily kilovoltage (kV) cone-beam computed tomography (CBCT) imaging
was performed to localize the PTV, and an automated fusion with the planning images yielded displacements
required for PTV re-localization. When the ERB volume and/or position were judged to yield inaccurate
repositioning, manual adjustment (ERB re-inflation and/or repositioning) was performed. Based on all 59
CBCT image sets acquired, a deformable registration algorithm was used to determine the dose received
by, displacement of, and deformation of the prostate, bladder, and anterior rectal wall. This dose tracking
methodology was applied to images taken before and after manual adjustment of the ERB (intervention), and
the delivered dose was compared to that which would have been delivered in the absence of intervention.
Results: Interventions occurred in 24 out of 35 (69%) of the treated fractions. The direct effect of these
interventions was a significant increase in the prostate radiation dose that included 95% of the PTV (D95)
from 9.6 ± 1.0 Gy to 10.0 ± 0.2 Gy (p=0.06) and a significant increase in prostate coverage from 94.0 ±
8.5% to 97.8 ± 1.9% (p=0.03). Additionally, ERB interventions reduced prostate deformation in the anterior-
posterior (AP) direction, reduced errors in the tilt of the prostate, and increased the similarity in shape of
the prostate to the radiotherapy plan (increased Dice coefficient from 0.76 ± 0.06 to 0.80 ± 0.04, p=0.01).
Post-intervention decreases in prostate volume receiving less than the prescribed dose and decreases in the
voxel-wise displacement of the prostate, bladder, and anterior rectal wall were observed, which resulted in
improved dose volume histogram (DVH) characteristics.
Conclusions: Image-guided interventions in ERB volume and/or position during prostate SBRT were
necessary to ensure the delivery of the dose distribution as planned. ERB interventions resulted in reductions
in prostate deformations that would have prevented accurate localization of patient anatomy.
I. INTRODUCTION
As external beam radiation delivery techniques become
more sophisticated, there has been a trend towards using
fewer fractions with a higher dose, or hypofractionation1.
An example of this is a common treatment known as
Stereotactic Body Radiation Therapy (SBRT), in which
an entire course of radiotherapy is given in only five
(or fewer) fractions. These treatments can be advan-
tageous due to radiobiological concerns, therapeutic ra-
tio, and patient convenience. However, care must be
taken to ensure accurate treatment planning and deliv-
ery, as these hypofractionated regimens usually involve
very high dose per fraction and relatively tight expan-
sion margins around the target volume.
a)Author to whom correspondence should be addressed:
bernard.jones@ucdenver.edu
SBRT can provide excellent clinical outcomes for se-
lected patients with prostate cancer2-7, a result thought
to stem from prostate cancer having a relatively low αβ
ratio, which favors a hypofractionated approach8,9. Crit-
ical to the success of SBRT are careful efforts to limit
the volume of the rectum and bladder that receive a high
dose. The prostate surrounds the urethra as it exits the
bladder and sits directly anterior to the rectum, mak-
ing it difficult to avoid these structures. Another com-
plicating factor is the contents of these two organs, as
changes in urine/stool volume can displace and deform
the prostate10-15, making it difficult to localize using rigid
transformations of the patient anatomy.
In many cases, an inflatable endorectal balloon (ERB)
is used during hypofractionated prostate treatment.
The ERB serves to reduce intrafraction motion of the
target16-18; however, care must be taken when actively
displacing the prostate via ERB use, especially in SBRT
when margins are small and dose per fraction is high.
Many studies have observed that in the similar situation
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FIG. 1. 3D geometry of prostate treatment. The prostate lies inferior/posterior to the bladder and anterior to the rectal wall.
The ERB expands the rectal wall and exerts force against the prostate in the anterior direction. The organs-at-risk (OAR) for
this treatment include the bladder and anterior rectal wall.
of inflatable endorectal coil use for MRI imaging of the
prostate, the gland may be compressed by as much as 1
cm in the anterior-posterior (AP) direction19-23. Proper
use of the ERB can also decrease rectal toxicity, as it
displaces the posterior rectal walls out of the high dose
regions24-26. Apart from a slight skin sparing effect at
the air/wall interface27, the ERB does not significantly
affect the dose absorbed by the anterior rectal wall24, and
thus when employing an ERB the rectal toxicity seen in
prostate radiotherapy28-30 is dependent on the anterior
rectal dose. With these factors in mind, it is necessary in
many cases to manually adjust the ERB volume and/or
position (intervene) after initial patient set-up to allow
for maximum agreement of the PTV, bladder, and rectal
wall positions between the radiotherapy plan and treat-
ment positions.
A similar situation exists in conventional radiotherapy
treatment of the prostate bed. An ERB is not commonly
used; however, changes in urine/stool volume can dis-
place and deform the prostate. A previous study exam-
ined the dosimetric impact of manual interventions on
rectal and bladder filling (i.e. stool and/or urine vol-
ume) in this scenario31. This study concluded that the
low frequency of interventions (16%) and the small pre-
scription dose per fraction (2 Gy) in a conventional frac-
tionation scheme diluted the effect of manual changes in
rectal and bladder filling, and there were no significant
differences in overall outcome from interventions when
daily cone beam computed tomography (CBCT) local-
ization was performed. However, because the conditions
are different for SBRT with ERB use, the effect of inter-
ventions could be significant.
In this work, the dosimetric impact of manual inter-
ventions of the ERB volume and/or position in patients
receiving SBRT to the prostate was assessed. This was
accomplished by retrospectively analyzing daily CBCT
images taken before and after manual adjustment of the
ERB (intervention), and comparing the delivered dose to
that which would have been delivered in the absence of
intervention. This work also assessed the relationship be-
tween ERB interventions and deformation of the shape
of the prostate.
II. METHODS
A. Patients
The data (59 CBCT image sets) of seven consecu-
tive patients with clinical stage T1cN0M0 prostate can-
cer who were enrolled in our institution as part of a
multi-institutional, IRB-approved trial of SBRT for low-
to-intermediate risk prostate cancer were studied32. The
patients (median age: 64 years; range: 56-69 years) were
treated with either static beam intensity modulated ra-
diotherapy (IMRT, n=1) or volumetric modulated arc
therapy (VMAT, n=6) on an Elekta Synergy accelerator
(Elekta, Crawley, UK) between January and December
2010.
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FIG. 2. Saggital slices of the pelvis showing the prostate (red),
bladder (yellow), and effect of ERB intervention. A) pCT im-
age showing radiotherapy planning position. B) CBCT image
showing pre-intervention ERB position. The ERB was not
inserted to the same depth as it was for the pCT scan, and
also exhibits a relative tilt. The shape of the prostate is no-
ticeably different. C) CBCT image showing post-intervention
ERB position, which more closely matches the pCT image.
B. Simulation, planning, and delivery
Prior to simulation, fiducial markers were implanted
into the prostate to assist in localization. To stabilize the
prostate and displace the posterior rectal wall, an ERB
inflated with 60 cm3 of air was used both during simu-
lation and delivery. Patients were simulated and treated
in the supine position. Patients were simulated on a CT
scanner utilizing contrast to identify the bladder and ure-
thra. Treatment planning was performed using either the
XiO IMRT or Monaco VMAT treatment planning sys-
tems (Elekta, St. Louis, MO). The PTV was generated
using expansion margins of 3 mm in all directions from
the prostate, and was prescribed to receive 50 Gy in five
fractions to 95% of the volume.
Per the clinical trial protocol32 the following structures
were contoured, and the following dose limits were ob-
served. The rectal wall was contoured from the superior
edge of the anal sphincter (inferiorly) to 1 cm above the
superior extent of the prostate. Assigning 0 to the most
anterior aspect of the rectum at mid-sagittal plane, the
anterior rectal wall was contoured from 315 to 45. The
contents of the bladder were excluded from the bladder
contour. The maximum point dose in the anterior rectal
wall, bladder, and prostatic urethra was limited to 105%
of the prescription dose. Additionally, no more than 10
cm3 of the bladder could receive in excess of 18.3 Gy.
All dose constrains were followed. Since the clinical trial
specifies a small PTV expansion margin (3-5 mm), ac-
curate delivery requires immobilization using an ERB,
localization using fiducial markers, daily image guidance
using CBCT, and physician review/approval for each de-
livered fraction. Full description of the protocol, patient
eligibility, treatment planning and dose constraints are
provided elsewhere32.
Before each fraction, localization of the prostate was
accomplished by acquiring a kilovoltage (kV) CBCT scan
and fusing it to the planning CT (pCT). By applying
rigid body translations to the CBCT, shifts were deter-
mined which resulted in the closest match between the
two scan positions. The first step in localization was to
align the three fiducial markers implanted in the prostate.
Second, the alignment of the ERB was compared to the
pCT. In 31% of the treatments, internal anatomy on the
CBCT and pCT matched sufficiently well to proceed with
treatment without manual adjustment (intervention).
For 24 of the 35 treatment fractions (69%), the initial
ERB placement was clinically judged to be insufficient
during localization to allow maximization of PTV cover-
age and organs-at-risk (OAR) sparing using only rigid-
body translations. For instance, it was seen in some cases
that the CBCT prostate extended outside the superim-
posed PTV contour. In other cases, misalignment of the
anterior ERB edge after alignment of the fiducial markers
was observed. For these cases, the position of the ERB
was manually re-adjusted to achieve better alignment.
An overview of the target and OAR geometry is shown
in Fig. 1, and an example ERB intervention is shown in
Fig. 2. In total, there were 24 pre-intervention image
sets, 24 post-intervention sets, and 11 fractions where
no intervention occurred. The act of intervening added
roughly 5-15 minutes to the total patient setup time.
C. Deformable Registration
To assess interfraction spatial displacement and dose
changes to individual voxels, the prostate, bladder, and
anterior rectal wall were contoured on each pre- and post-
intervention CBCT (59 total CBCT image sets). The
contours were drawn by the same physician and reviewed
by the same physicist for intra- and inter-observer con-
sistency. The voxel tracking process was adapted from a
previous study of prostate bed deformations31 and pro-
ceeded as follows using software developed by the cur-
rent authors. First, a set of matching control points
for each organ was computed based on the CBCT and
4pCT contours. The control points were selected in or-
der to best capture the known mechanics of deforma-
tion in the prostate and rectal wall. It has been shown
that ERBs lead to little prostate deformation along the
superior-inferior axis20. It is also generally assumed
that changes in rectal filling only stretch the rectal wall
transversely33, and this assumption is reinforced by the
constraints placed on the rectal wall contour in the axial
direction32 (i.e. uniform axial length). Thus, the control
points for each slice were selected along the contours at
equal angular intervals from the slice centroid, which cap-
tures expansion and contraction of the contours in the ax-
ial plane while preventing non-physical rotation that can
occur in deformable registration of spheroid/cylindrical
shapes, such as the prostate, bladder, and rectum.
Based on the displacements between matching control
points, a pCT-to-CBCT deformation field was generated
for each organ using thin-plate spline warping34. Using
this deformation field, each voxel within the pCT con-
tour was deformed to a new location in the CBCT. To
calculate the pre-/post-/no intervention voxel-wise dis-
placement of each organ, couch shifts were applied to the
CBCT dataset such that the coordinates of the scan rep-
resented the geometry that was either used for treatment
(in the case of post- or no intervention) or would have
been used for treatment in the absence of intervention
(pre-intervention).
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FIG. 3. Axial slice of the prostate and ERB demonstrating
displacement and deformation. Left) The ERB is placed in-
correctly at time of treatment, causing the prostate to shift
in the AP direction from the plan position. A deformable al-
gorithm is used to determine the displacement of each voxel
in the prostate in order to determine dose received during
treatment. Right) The same algorithm is applied after rigid
alignment of the two prostate structures in order to quantify
the deformation (i.e. difference in shape) of each voxel.
D. Displacement/Deformation and Dose
Using the pCT-to-CBCT deformation field, the vec-
tor translation of each voxel from its position in the
pCT geometry to a new position in the CBCT geom-
etry was calculated. By applying this methodology to
each CBCT image set, the location of each voxel in the
pCT structures was tracked throughout all pre-/post-/no
intervention treatments. Doses were not recalculated on
the CBCT images due to effects such as x-ray scatter,
detector glare, and image lag, which cause the images to
contain CT-to-electron density variations too large for ac-
curate dose calculation35. To calculate the dose received
in the pre- or post-intervention geometry, each voxel was
translated within the planning dose field (based on the
pCT-to-CBCT deformation field). In other words, the
planning dose field was superimposed on the CBCT ge-
ometry.
Based on the displacement and dose information, sev-
eral dosimetric parameters were calculated for pre- and
post-intervention treatments. PTV Coverage was defined
as the fraction of the deformed CBCT prostate volume
that was within the PTV. Dx was the lowest dose re-
ceived by the highest x% of the volume, and Vx was the
volume receiving >x dose.
To analyze the deformations in prostate shape, a
second pCT-to-CBCT deformation field was calculated.
First, a rigid registration was performed between the
pCT and CBCT prostate contours by minimizing the
total distance between matching control points. Then,
using the previously described methodology, the vector
translation of each voxel in the prostate from the pCT to
CBCT was calculated. By aligning the two structures be-
fore applying the control point-based deformation field,
the calculated deformations more accurately represent
changes in the shape of the prostate, and exclude any
systematic shifts that may be present due to imperfect
alignment or prioritization of OAR sparing above target
coverage. Throughout the following text, deformation
refers to the changes in shape (i.e. vector translation of
each voxel based on pCT-to-CBCT deformation field af-
ter rigid alignment of the prostate), while displacement
refers to changes in absolute position, or in other words
changes in shape in addition to any rigid-body misalign-
ment. The differences between these two quantities are
demonstrated in Fig. 3.
To quantify differences in the shape of the prostate,
the Dice coefficient was calculated between each pCT and
CBCT prostate contour (after rigid alignment). The Dice
coefficient (D) is a measure of the similarity of two pixel
sets, and ranges from 0 to 1 for shapes with no overlap
to perfect overlap, respectively. The Dice coefficient36 is
calculated via Eq. 1, where |C1∩C2| is the volume of all
overlapping voxels between two contours, and |Cn| is the
total volume of a contour.
D =
2|C1∩C2|
|C1|+ |C2| (1)
III. RESULTS
A. Single-fraction Impact
Since the SBRT technique involves a higher dose per
fraction and a smaller number of fractions (compared
5Dose Difference Displacement
I
A
S R
L
P
cm/fx
0
0.2
0.4
0.6
0.8
1
cm/fx
0
0.2
0.4
0.6
0.8
1
Gy/fx
3
2
1
0
-1
-2
-3-2
-1.6
-1.2
-0.8
-0.4
0
Gy/fx
A B A B A B A B
Prostate Ant Rectal Wall Prostate Ant Rectal Wall
Pt. 1
Pt. 2
Pt. 3
Pt. 4
Pt. 5
FIG. 4. Patient-specific changes in dose to and displacement of the prostate and ARW, where each row represents the
prostate/ARW of a different patient. For each patient with > 1 intervention, the dose and displacement of each voxel was
averaged within all pre- and post-intervention treatments (denoted as columns A and B, respectively), based on the voxel-wise
displacements computed from CBCT contours. Doses on the surface of the prostate are displayed as the difference from the
prescription dose of 10 Gy/fx; thus, any non-zero data points represent under-dosing of the prostate. Doses to the anterior
rectal wall are displayed as the average difference per fraction from the treatment plan dose. In the prostate, the cumulative
effect of intervening was an increase in target coverage and a decrease in surface displacement from the planning prostate shape.
In the ARW, the cumulative effect of intervention was that the resultant doses more closely resembled the plan dose, and that
there was a decrease in surface displacement near the ERB/prostate interface.
to conventional treatments), significant deviations in a
single fraction could have a large impact on the over-
all treatment outcomes. In order to compare the effects
of ERB adjustments between patients, dosimetric pa-
rameters of interest were calculated for each fraction in
which an ERB adjustment (intervention) was performed
(Fig 2). The direct dosimetric effects of ERB adjust-
ments are shown in Table 1 for PTV, anterior rectal wall
(ARW), and bladder (BLA). These data are the mean
values based on the paired results of all 48 pre- and post-
intervention CBCTs. P-values are shown for a paired
t-test of the hypothesis of equal means.
It can be seen that there were significant increases in
both D95 to the prostate and in the prostate coverage.
However, there was no significant change in the dosimet-
ric parameters of the anterior rectal wall or bladder. This
was due to the fact that the primary objective in aligning
the patient was target coverage, thus interventions may
either increase or decrease dose to normal tissue.
TABLE I. Single-fraction dosimetric effect of manual ERB
adjustment (n=24)
Pre-Intervention Post-Intervention p
PTV D95 (Gy) 9.64 ±1.0 10 ±0.2 0.06
PTV Cov (%) 94.6 ±7.6 98.0 ±1.9 0.03
ARW V6 (cm3) 9.1 ±2.8 9.3 ±2.2 0.47
ARW V8 (cm3) 7.1 ±3.0 7.4 ±2.4 0.49
ARW V10 (cm3) 3.3 ±1.6 2.7 ±1.2 0.17
BLA V2 (cm3) 31 ±12 29 ±10 0.17
BLA V4 (cm3) 20 ±11 19 ±8.9 0.45
BLA V6 (cm3) 14 ±10 13 ±7.8 0.36
Abbreviations: PTV=planning target volume,
Cov=coverage, ARW=anterior rectal wall, BLA=bladder,
Vx=volume receiving >x Gy per fraction, Dx=lowest dose
received by the highest x% of the volume.
B. Patient-specific Impact
Interventions were performed for 69% of all treated
fractions, with an average of three interventions per pa-
tient. To visualize the effects that interventions could
have on a single patient, Fig. 4 shows the dose differ-
6FIG. 5. Effect of ERB interventions on the position of each voxel in the prostate, anterior rectal wall, and bladder. Deformation
represents the changes in shape, while displacement represents changes in shape in addition to any rigid-body misalignment.
In all cases (a-c), the displacement of each organ relative to the radiotherapy plan was reduced as a result of interventions.
Additionally, the deformation of the prostate (d) was reduced.
ence and displacement along the surface of the prostate
and ARW for all patients with more than 1 intervention.
Each row in these figures shows the prostate/ARW of a
different patient. For the prostate, the dose is displayed
in terms of the difference from the planned dose of 10
Gy/fraction; thus, any non-zero data points represent
under-dosing of the prostate. For the ARW, the dose is
displayed as the difference from the radiotherapy plan
dose for that voxel. In both cases, the displacement is
shown in terms of average absolute displacement of each
voxel from the pCT (based on the pCT-to-CBCT de-
formation field). To allow comparison between patients
with different numbers of interventions, each plot shows
the dose and displacement changes averaged over all in-
tervened fractions (mean change per intervened fraction).
The number of voxels in the prostate receiving less
than the prescription dose was decreased as a result of
interventions. This can be attributed to the reductions
in displacement also seen in Fig. 4. A particularly large
change is seen in the last row of Fig. 4; in that case,
the ERB did not inflate properly, leading to very large
deformations in the shape of the prostate and rectum. In
the ARW, note that these values can yield insight into
the ERB position/ARW shape during treatment. For in-
stance, a dose increase on the ARW surface below the
visible ERB bulge implies that the ERB was slightly
lower during treatment, pushing this inferior portion of
the ARW into the treatment field. In nearly all voxels,
the cumulative effect of intervention was that the resul-
tant dose distributions more closely resembled the plan
dose, especially along the ARW/prostate interface, which
receives the highest dose. The displacement seen in this
area was also greatly reduced.
C. Cumulative Impact
To understand the effect of ERB interventions on the
position and shape of the prostate, ARW, and bladder,
the displacement of each voxel for all 24 pre- and post-
intervention fractions was pooled and analyzed. His-
tograms of the absolute displacement per voxel for the
prostate, bladder, and anterior rectal wall are shown in
Fig. 5 a-c. The overall effect of ERB interventions was a
reduction in voxel-wise displacement for all organs under
consideration.
To understand the dosimetric effects that interventions
have on an entire course of treatment, a dose-volume his-
togram of the overall treatment effect is shown in Fig. 6.
In fractions where no intervention occurred (n=11), the
7doses based on the CBCT for that fraction were used for
both pre- and post-intervention. In other words, this fig-
ure shows the actual doses delivered alongside the doses
that would have been delivered in the absence of inter-
ventions in 24 of 35 fractions. In all three organs under
consideration, intervention resulted in a dose distribution
that more closely resembled the treatment plan.
D. Effect of Intervention on Prostate Shape
Figs. 4 and 5a show the displacement in the shape
of the prostate between the treatment position and the
plan position. This is useful for comparing the direct ef-
fects of ERB interventions on delivered dose; however, it
does not give an accurate picture of the true deforma-
tion experienced by the prostate because there are two
conflicting goals in the alignment of the patient during
treatment: PTV coverage and OAR sparing. Thus, the
treatment position may not reflect a true rigid alignment
between the planning and treatment prostate shapes.
Fig. 5d shows the cumulative effect of ERB interven-
tions on deformations in the shape of the prostate. As
shown in Fig. 5d, the number of voxels experiencing a
deformation in excess of roughly 5 mm decreased, and
the number of voxels deformed by less than 5 mm in-
creased. Additionally, Table 2 shows the effect of ERB
interventions on a number of parameters which describe
the shape of the prostate. The most significant improve-
ments in prostate shape were a decrease in AP deforma-
tion, a decrease in the tilt of the prostate in the sagittal
plane, and an increase in the Dice coefficient between the
planning and treatment shapes. P-values are shown for
a paired t-test of the hypothesis of equal means.
TABLE II. Effect of manual ERB adjustment on prostate
shape (n=24)
Pre-Intervention Post-Intervention p
AP def. (mm) 3.4 ±1.1 2.8 ±1.1 0.02
LR def. (mm) 2.6 ±0.7 2.3 ±0.7 0.11
SI def. (mm) 0.4 ±0.3 0.4 ±0.3 0.73
Sagittal Tilt (◦) 15 ±8.2 10 ±6.0 0.09
Dice Coef. 0.76 ±0.06 0.8 ±0.04 0.01
Abbreviations: AP=anterior-posterior, LR=left-right,
SI=superior-inferior, def=deformation
IV. DISCUSSION
A previous study31 found that interventions in rectal
and bladder filling were not necessary for patients under-
going post-prostatectomy radiation therapy with conven-
tional fractionation and daily CBCT localization. How-
ever, one expects the analogous scenario of ERB interven-
tion in SBRT to be more significant for several reasons:
namely, the increased frequency of intervention (69% vs.
16%), higher doses per fraction (10 Gy vs. 2 Gy), and
tighter treatment margins (3 mm vs. 5-10 mm). Us-
ing an ERB can be dosimetrically advantageous due to
a reduction of intrafraction motion of the prostate16-18
and lower dose to the posterior rectal wall24-26. However,
ERB use extends the time required for setup/treatment,
can cause patient discomfort, and has the possibility to
introduce localization errors due to improper positioning
and/or inflation. The results of our study show that ERB
position can have a significant impact on the dosimetry
of each fraction, and that manual interventions can bring
about an increase in prostate D95 and coverage. It should
be noted that the effects presented here were seen using
an ERB with 60 cm3 volume. As a larger/smaller ERB
would exert different forces on the prostate, these results
may differ for other sizes of ERB in clinical use.
A. Prostate Metrics
We have shown here that interventions in ERB posi-
tion lead to improved dosimetric outcomes for the treat-
ment of prostate cancer. This is evidenced by the
post-intervention decreases in dose difference and sur-
face displacement (Fig. 4), post-intervention increases
in prostate D95 and coverage (Table 1), decreases in dis-
placement and deformation of the prostate (Fig. 5a and
d), and improved overall DVH characteristics (Fig. 6).
While the prostate dosimetric outcomes are higher in the
post-intervention case, it is not certain whether or not the
differences in the population-averaged metrics are clini-
cally significant. However, it is apparent from Fig. 4 that
the effects of interventions can be quite large on the in-
dividual level. Taken together, these results suggest that
ERB interventions are necessary to ensure the delivery
of dose distributions as planned.
This has several implications for radiotherapy of the
prostate using SBRT. First, it implies that two CBCT
scans are generally needed for adequate target localiza-
tion: one after insertion of the ERB and one after ad-
justment (if necessary). Second, it supports the idea that
careful review of the patient anatomy and target local-
ization are crucial for target coverage.
B. ERB Position
We found that ERB position interventions lead to an
overall decrease in the amount of deformation of the
prostate compared to the planning position (Fig. 5d and
Table 2). Fig. 7 demonstrates one possible mechanism
for these effects. This plot shows the structures from the
pCT and CBCT of a particular pre-intervention fraction.
In this setup, the ERB centroid is lower than planned as
a result of insufficient insertion depth. This manifests as
an inferior shift in the point of contact between the an-
terior rectal wall and the ERB. As a result, the prostate
is deformed in the AP and superior-inferior (SI) direc-
8FIG. 6. Cumulative DVH for pre-/post-intervention and planned dose based on all 35 treated fractions. In fractions where no
intervention occurred (n=11), the doses based on the CBCT for that fraction were used for both pre- and post-intervention. In
other words, Post-Intv represents the total doses delivered to the patients, and Pre-Intv represents the total doses that would
have been delivered, had no interventions occurred.
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FIG. 7. Effect of rectal balloon (ERB) position on prostate
deformation in one sample treatment fraction. A patient is
simulated with an ERB originally at position (A) in the plan
CT. During treatment, the ERB is placed at position (B), and
the anterior edge of the ERB is displaced towards the base of
the prostate. This causes the prostate, originally simulated in
position (C), to be displaced/deformed superiorly to position
(D).
tions, and tilted in the sagittal plane. Since this shape
differs from the planning prostate, it is difficult to cover
the prostate with the existing fields, which are shaped by
the MLCs to conform very precisely to the pCT prostate
shape. In other words, no combination of rigid transla-
tions will allow the conformal treatment fields to cover a
deformed prostate, and coverage suffers as a result.
One possible solution to this problem would be to gen-
erate an updated treatment plan based on the patients
daily anatomy (Adaptive Radiotherapy). However, this
carries its own set of challenges, especially in terms of
the reduced quality of CBCT, the workload required to
generate a plan in real time, and the ability to verify the
treatment before delivery.
C. Anterior Rectal Wall and Bladder
There was no significant reduction or improvement in
dose metrics for the anterior rectal wall or bladder. How-
ever, the overall effect of ERB interventions was to reduce
deformations in these structures between the planning
and treatment position, resulting in delivered dose distri-
butions that more closely resembled the treatment plan.
Improper ERB position can push the prostate out of the
field, leading to a decrease in coverage; however, if the
ERB were placed incorrectly it could cause either an in-
crease or decrease in dose to the rectum and bladder. It
was seen that there was no change in mean value, as these
changes negate each other when calculating the dose met-
rics for anterior rectal wall or bladder. However, these
post-intervention values conform better to the treatment
plan (Fig. 5).
V. CONCLUSIONS
With the use of ERBs during prostate SBRT, inter-
ventions in ERB position are frequently necessary to en-
sure the delivery of the dose distribution as planned.
We found that interventions lead to significant post-
intervention increases in prostate D95 and coverage, de-
creases in displacement at the time of treatment of the
prostate, and improved post-intervention DVH charac-
teristics for PTV, anterior rectal wall, and bladder. We
also found that ERB adjustments lead to decreases in de-
formation of the prostate in the AP direction, decreases
in the tilt of the prostate from the planning position, and
9an increase in the similarity in shape (Dice coefficient)
between the planning and treatment prostate shapes.
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